Form 4: Director Shalini Sharp Receives NBIX Equity Grant

Neurocrine Biosciences Director Shalini Sharp was granted 2,567 restricted stock units vesting in May 2027.

Summary

• Director Shalini Sharp acquired 2,567 Restricted Stock Units (RSUs) on May 27, 2026.
• Each RSU represents a contingent right to receive one share of Neurocrine Biosciences common stock.
• The grant is subject to a one-year vesting schedule, with full vesting occurring on May 27, 2027.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation, which carries a neutral sentiment.

Positives

• Alignment of director interests with long-term shareholder value through equity-based compensation.

Negatives

• None identified.

Risks

• Standard market risks associated with equity ownership and potential share price volatility.

Future Outlook

The RSUs are scheduled to vest in full on May 27, 2027, at which point the director will receive common stock.

Industry Context

StockSavvy.ai notes that equity grants to board members are standard corporate governance practice in the biotechnology sector to ensure director retention and alignment with long-term corporate performance.

Comparison to Industry Standards

• The grant of RSUs to non-employee directors is consistent with standard compensation practices for mid-to-large cap biopharmaceutical companies.
• The one-year cliff vesting period is a common retention mechanism used by peers such as Vertex Pharmaceuticals and BioMarin.

Stakeholder Impact

• Minimal impact on existing shareholders as this represents a standard director compensation event.

Next Steps

• Vesting of the 2,567 RSUs on May 27, 2027.

Key Dates

Keywords

Neurocrine Biosciences, NBIX, Form 4, Insider Trading, Equity Compensation, Director Compensation